Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $16,610.88 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 1,936 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $8.58, for a total transaction of $16,610.88. Following the sale, the insider now owns 142,768 shares of the company’s stock, valued at approximately $1,224,949.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Scholar Rock Trading Up 10.3 %

Shares of SRRK opened at $9.39 on Friday. Scholar Rock Holding Co. has a twelve month low of $6.03 and a twelve month high of $21.17. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $751.48 million, a P/E ratio of -4.49 and a beta of 0.82. The firm’s 50-day moving average is $8.93 and its two-hundred day moving average is $11.23.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same period in the previous year, the company earned ($0.47) earnings per share. On average, research analysts predict that Scholar Rock Holding Co. will post -2.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a research note on Tuesday, June 25th. Finally, BMO Capital Markets increased their price target on shares of Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $26.43.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRRK. Swiss National Bank lifted its stake in shares of Scholar Rock by 17.3% during the 4th quarter. Swiss National Bank now owns 98,100 shares of the company’s stock worth $1,844,000 after purchasing an additional 14,500 shares during the period. Amalgamated Bank lifted its position in Scholar Rock by 15.5% during the fourth quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock worth $92,000 after buying an additional 652 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Scholar Rock by 30.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company’s stock worth $7,410,000 after buying an additional 91,754 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Scholar Rock by 616.8% in the 4th quarter. BNP Paribas Financial Markets now owns 48,372 shares of the company’s stock valued at $909,000 after buying an additional 41,624 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Scholar Rock during the 4th quarter valued at about $1,359,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.